Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Non-Current Debt (2016 - 2025)

Northwest Biotherapeutics' Non-Current Debt history spans 15 years, with the latest figure at $12.3 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $12.3 million for Q4 2025, down 0.51% from a year ago — trailing twelve months through Dec 2025 was $12.3 million (down 0.51% YoY), and the annual figure for FY2025 was $12.3 million, down 0.51%.
  • Non-Current Debt for Q4 2025 was $12.3 million at Northwest Biotherapeutics, up from $7.2 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $25.2 million in Q4 2021 to a low of $5.9 million in Q3 2022.
  • The 5-year median for Non-Current Debt is $12.4 million (2021), against an average of $13.7 million.
  • The sharpest move saw Non-Current Debt surged 290.64% in 2021, then tumbled 76.18% in 2022.
  • Year by year, Non-Current Debt stood at $25.2 million in 2021, then tumbled by 76.18% to $6.0 million in 2022, then soared by 239.04% to $20.3 million in 2023, then plummeted by 38.97% to $12.4 million in 2024, then fell by 0.51% to $12.3 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $12.3 million, $7.2 million, and $9.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.